Caris Life Sciences vs Castle Biosciences
CAI and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and CSTL compare
Caris Life Sciences is the larger company, worth 5.6 times as much as Castle Biosciences ($5.6B against $1.0B).
Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 9.8% for Castle Biosciences).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −6.1% at Castle Biosciences.
Castle Biosciences scores higher on the StockData Score (11 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | $5.6B | $1.0B |
| Share price | $19.94 | $32.98 |
| Change, 1 year | −16.4% | −1.4% |
| Change, 5 years | – | −23.5% |
| Beta (5Y) | 2.53 | 0.68 |
| Employees | 1,846 | 883 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.4× | 2.7× (better) |
| P/B | 8.8× | 2.1× (better) |
| EV/EBITDA | 36.5× | – |
| P/FCF | 195× (better) | 254× |
| FCF yield | 0.51% (better) | 0.39% |
| Fair value | $10.35 | $34.22 |
| Margin of safety | −92.6% | 3.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 61.5% (better) | 9.8% |
| Revenue growth, 5Y average | – | 40.6% |
| Profitability | ||
| Gross margin | – | 77.1% |
| Operating margin | 13.4% (better) | −7.4% |
| Net margin | 9.2% (better) | −6.1% |
| FCF margin | 2.8% (better) | 1.1% |
| Return on equity | 17.2% (better) | −4.9% |
| Return on invested capital | 26.8% (better) | −11.1% |
| Financial health | ||
| Debt / equity | 0.61 | 0.02 (better) |
| Net debt / EBITDA | 1.79 | – |
| Interest coverage | 3.3× (better) | −51.2× |
| Current ratio | 6.71 (better) | 5.28 |
| Altman Z-score | 4.73 | 6.49 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | 0.56% | – |
| Shareholder yield | 0.56% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 89.5% |
| Held by insiders | 64.1% | 1.9% |
| Insider net buying, 12 months | −$27.4M | −$18.4M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 11.3% | 7.0% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.